Partnerships Target Protein Enhancement | May 25, 2009 Issue - Vol. 87 Issue 21 | Chemical & Engineering News
Volume 87 Issue 21 | p. 16 | Concentrates
Issue Date: May 25, 2009

Partnerships Target Protein Enhancement

Department: Business

Two pairs of companies have signed deals around technology that improves the availability and longevity of pharmaceutical proteins in the body. Fresenius Kabi and Bayer Schering Pharma have signed a research, development, and licensing agreement that gives Bayer access to Fresenius' HESylation technology, in which drugs are modified with hydroxyethyl starch. Meanwhile, Novozymes and Human Genome Sciences have revised an agreement over Novozymes' Albufuse, a technology for fusing protein drugs with albumin. Novozymes says the revision gives it the "necessary platform" to commercially exploit the process.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment